Post-corticosteroid Insufficiency: Search for a Threshold Value for Cortisol at 8 Hours, Prospective Study (SYNASTOPRO)

Post-corticosteroid insufficiency is found in 40-60% of patients within 10 weeks following the cessation of prolonged corticosteroid therapy and in 20% of patients still after 1 year. Screening in pediatrics is done by carrying out a dynamic test, often the low-dose Synacthen test, which requires day hospitalization. The investigators established in a single-center retrospective study that plasma cortisol at the start of the test could predict the result of the low-dose Synacthen test in patients treated with chronic corticosteroid therapy using two thresholds. A cortisol < 144 nmol/L makes it possible to predict corticotropic insufficiency with a specificity of 94%, while a plasma cortisol > 317 nmol/L eliminates corticotropic insufficiency with a sensitivity of 95%. These thresholds need to be confirmed by a prospective study, and in a population representative of the diversity of children treated with prolonged corticosteroid therapy. Furthermore, certain studies have demonstrated the benefit of salivary cortisol compared to plasma cortisol. Performing salivary cortisol could facilitate screening in consultation.

Study Overview

• Status: Not yet recruiting
• Conditions: Glucocorticoid-induced Adrenal Insufficiency
• Intervention / Treatment: Diagnostic test: Salivary cortisol dosage

Detailed Description

Synthetic glucocorticoids are widely used in medicine for their anti-inflammatory and immunomodulating effects. There are 1-2% of the population treated with synthetic glucocorticoids; among them, around 0.5% underwent prolonged treatment. Glucocorticoids act to reduce inflammation, to modulate immunity but also, to regulate physiological functions such as glucose or bone homeostasis. This is why, despite great efficiency, glucocorticoids are associated with numerous side effects. One of the most frequent is glucocorticoid-induced adrenal insufficiency (GI-AI), which is caused by exogenous glucocorticoid negative feedback on the pituitary and the hypothalamus that leads to adrenal insufficiency. Within 10 weeks after glucocorticoid treatment withdrawal, more than 40% of the patients displayed biological glucocorticoid insufficiency. It is important to diagnose GI-AI to prevent life-threatening adrenal crisis. Diagnosis of GI-AI is biological. In pediatrics, the Low Dose Short Synacthen Test (LD-SST) is usually used. LD-SST consists of injection of a low dose of Synacthen (1µg) to stimulate the adrenal glands and evaluate their capacity to secrete a cortisol peak superior to 500 nmol/L. Plasma cortisol elevation is measured at T20, T30, and T60 and compared to an unstimulated value at T0. As LD-SST requires an outpatient hospital and multiple blood samples, less than 5% of the patients underwent adrenal testing after prolonged glucocorticoid treatment.

In a retrospective study, the investigators showed that morning plasmatic cortisol value can be used to predict LD-SST outcomes, facilitating GI-AI diagnosis. Based on 91 pediatric patients who underwent LD-SST after prolonged glucocorticoid therapy, the investigators showed that a morning plasma cortisol value superior to 317 nmol/L could rule out the diagnosis of GI-AI with a sensitivity of 95% whereas a value inferior to 144 nmol/L is associated with GI-AI with a specificity of 94%. However, our study had several limits, such as selection bias and population representativity, and those thresholds needed to be confirmed with a larger prospective study.

The main objective of our study is to confirm thresholds of morning plasma cortisol value to diagnose glucocorticoid-induced adrenal insufficiency in a larger population, more representative of the variety of glucocorticoid treatment in pediatrics. Secondary objectives are the evaluation of salivary cortisol values either to replace plasma cortisol value in response to Synacthen or as a single morning cortisol value. The tertiary objective is to determine GI-AI prevalence in children treated with glucocorticoids for more than 3 weeks and to evaluate clinical predictive factors.

It is a prospective bicentric study. The investigator will include patients aged from 6 months to 18 years old who underwent glucocorticoid treatment for at least 3 weeks at a dose superior to or equal to 3 mg/m2/day. As asthma is the most common pediatric pathology to require prolonged glucocorticoid treatment, patients treated with inhaled glucocorticoids for more than 12 months, or more than 6 months if associated with topic glucocorticoids or if the dose is considered high (GINA 2022) will also be included.

Four weeks after treatment discontinuation or tapering, an LD-SST will be performed to diagnose GI-AI. It will be associated with salivary cortisol measurement at T0 and T30. The investigators will evaluate the association between T0 plasma or salivary cortisol values and GI-AI (plasma cortisol < 500 nmol/L after LD-SST). Thresholds of morning plasma or salivary cortisol associated with the presence or absence of GI-AI will be determined using a receiver operating characteristic (ROC) curve. The risk factors of GI-AI will be assessed through linear regression.

The investigators believe that using morning plasma or salivary cortisol values to screen patients after glucocorticoid withdrawal should improve systematic GI-AI screening and, thus, prevention of adrenal crisis.

• Study Type: Interventional
• Enrollment (Estimated): 170
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Caroline STOREY, MD; Phone Number: +33.1.85.55.27.43; Email: caroline.storey@aphp.fr
• Study Contact Backup: Name: Margaux LAULHE, MD; Phone Number: +33.1.40.03.53.03; Email: margaux.laulhe@aphp.fr

Study Locations

• France
  • Paris, France, 75019
    • Robert Debré Hospital
    • Contact: Caroline STOREY, MD; Phone Number: +33.1.85.55.27.43; Email: caroline.storey@aphp.fr
    • Contact: Margaux LAULHE, MD; Phone Number: +33.1.40.03.53.03; Email: margaux.laulhe@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 6 months - 17 years
• Treatment with glucocorticoids for at least 3 weeks at doses ≥ 3 mg/m2 prednisone equivalent OR Treatment with inhaled corticosteroids (ICS) for > 12 months OR high-dose ICS > 6 months OR ICS > 6 months at any dose in combination with other topical corticosteroids.
• Withdrawal of corticosteroid therapy EXCEPT ICS and topical corticosteroids (tapering off) and/or replacement therapy (< 3 mg/m2/day, eq. Prednisone) for at least 4 weeks.
• Prescription for Synacthen test including 4 blood samples (T0, T20, T30, T60)
• No objection from a legal representative or the child taken in by the doctor

Exclusion Criteria:

• Use of glucocorticoids INCLUDING TOPICALS AND ICS in the 12 hours preceding the test
• Opposition of the child or legal guardians

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Salivary cortisol dosage; saliva sample (1 ml) at 8 & 9 h & at T30	Diagnostic test: Salivary cortisol dosage; saliva sample at 8 - 9h & at T30

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma cortisol	morning plasmatic cortisol threshold associated with glucocorticoid-induced adrenal insufficiency defined by the Low Dose Short Synacthen Test (LD-SST) response	60 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Salivary cortisol (nmol/L)	morning salivary cortisol thresholds to predict glucocorticoid-induced adrenal insufficiency measured by LD-SST / Evaluation of salivary cortisol at T30 after Synacthen to replace plasma cortisol assessment	30 minutes

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Caroline STOREY, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2024
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): April 1, 2026

Study Registration Dates

• First Submitted: January 5, 2024
• First Submitted That Met QC Criteria: January 5, 2024
• First Posted (Actual): January 17, 2024

Study Record Updates

• Last Update Posted (Actual): January 17, 2024
• Last Update Submitted That Met QC Criteria: January 5, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Low Dose Short Synacthen Test (LD-SST)
• Additional Relevant MeSH Terms: Endocrine System Diseases; Adrenal Gland Diseases; Adrenal Insufficiency; Anti-Inflammatory Agents; Hydrocortisone
• Other Study ID Numbers: APHP230745; IDRCB: 2023-A01217-38 (Registry Identifier: IDRCB ANSM)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No